These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 6129559)

  • 21. First ultra-short-acting beta-adrenergic blocking agent: its effect on size and segmental wall dynamics of reperfused myocardial infarcts in dogs.
    Lange R; Kloner RA; Braunwald E
    Am J Cardiol; 1983 Jun; 51(10):1759-67. PubMed ID: 6134464
    [No Abstract]   [Full Text] [Related]  

  • 22. Combined receptor intervention and myocardial infarction.
    Chamberlain DA; Vincent R
    Drugs; 1984; 28 Suppl 2():88-108. PubMed ID: 6151893
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ultra-short-acting beta-adrenergic receptor blocking agents. 2. (Aryloxy)propanolamines containing esters on the aryl function.
    Erhardt PW; Woo CM; Anderson WG; Gorczynski RJ
    J Med Chem; 1982 Dec; 25(12):1408-12. PubMed ID: 6130154
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Double-blind study of the effect of cardioselective beta-blockade on chest pain in acute myocardial infarction.
    Waagstein F; Hjalmarson AC
    Acta Med Scand Suppl; 1976; 587():201-8. PubMed ID: 3098
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Benefits of non-selective versus cardioselective beta-blockers in acute myocardial infarction in hypertensive patients.
    Hansen O; Johansson BW
    J Hypertens Suppl; 1993 Jun; 11(4):S55-60. PubMed ID: 8104242
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of intracoronary administration of a short-acting β-blocker landiolol during reperfusion in pigs.
    Park H; Otani H; Oishi C; Fujikawa M; Yamashita K; Okazaki T; Sato D; Ueyama T; Iwasaka J; Yamamoto Y; Iwasaka T
    Int J Cardiol; 2011 Feb; 146(3):347-53. PubMed ID: 19709770
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ultra-short-acting beta-adrenergic blockers.
    Frishman WH; Murthy S; Strom JA
    Med Clin North Am; 1988 Mar; 72(2):359-72. PubMed ID: 2894487
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacodynamics and onset of action of esmolol in anesthetized dogs.
    Quon CY; Gorczynski RJ
    J Pharmacol Exp Ther; 1986 Jun; 237(3):912-8. PubMed ID: 2872328
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Cardioselective beta receptor blockade in acute myocardial infarct with talinolol].
    Assmann I; Fiehring H; Oltmanns G; Kulick B; Kretzschmar E
    Z Gesamte Inn Med; 1981 Sep; 36(18):637-44. PubMed ID: 6118980
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics and pharmacodynamics of beta blockers in heart failure.
    Talbert RL
    Heart Fail Rev; 2004 Apr; 9(2):131-7. PubMed ID: 15516861
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Beta blockers in post-infarction state].
    Schultheiss HP; Tschöpe C
    Herz; 2002 Aug; 27 Suppl 1():26-9. PubMed ID: 12229255
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Characteristics of medical use of Korvazan® for restorative treatment of patients with myocardial infarction, counting the risk factors].
    Vakaliuk IP; Tymochko NB
    Lik Sprava; 2013 Dec; (8):94-9. PubMed ID: 25726684
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Esmolol and beta-adrenergic blockade.
    Wolman RL; Fiedler MA
    AANA J; 1991 Dec; 59(6):541-8. PubMed ID: 1686346
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The use of short-acting beta-blockers in cardiac surgery].
    Van Besouw J
    Rev Esp Anestesiol Reanim; 2001 Dec; 48(10):482-6. PubMed ID: 11792307
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial.
    Dargie HJ
    Lancet; 2001 May; 357(9266):1385-90. PubMed ID: 11356434
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of beta blockers, particularly carvedilol, on reducing the risk of events after acute myocardial infarction.
    Kopecky SL
    Am J Cardiol; 2006 Oct; 98(8):1115-9. PubMed ID: 17027583
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Beta-blockers for the post-myocardial infarction patient: current clinical evidence and practical considerations.
    Fonarow GC
    Rev Cardiovasc Med; 2006; 7(1):1-9. PubMed ID: 16534490
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improved myocardial protection using continuous coronary perfusion with normothermic blood and beta-blockade with esmolol.
    Mehlhorn U
    Thorac Cardiovasc Surg; 1997 Oct; 45(5):224-31. PubMed ID: 9402661
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Esmolol, the first ultra-short-acting intravenous beta blocker for use in critically ill patients.
    Blanski L; Lutz J; Laddu A
    Heart Lung; 1988 Jan; 17(1):80-9. PubMed ID: 3276651
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of an ultra short-acting beta-blocker in patients with acute myocardial ischemia.
    Kirshenbaum JM; Kloner RA; Antman EM; Braunwald E
    Circulation; 1985 Oct; 72(4):873-80. PubMed ID: 2863013
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.